Oncology JP Morgan 2023 - Raj Chopra On the sidelines of JP Morgan 2023, pharmaphorum editor-in-chief Jonah Comstock sat down with Raj Chopra, acting CEO of Aethon Therapeutics.
Oncology After a slow start for expensive CAR-T therapies, drug devel... There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T cell and injected antibody therapies have led drug developers to look at novel o
Oncology Economist Impact: World Cancer Series – pharmaphorum in atte... Taking a brief look back to pharmaphorum’s coverage of Day One of The Economist’s 8th Annual
News EU approves AZ's Imfinzi plus chemo for advanced biliary tra... AstraZeneca’s (AZ) Imfinzi (durvalumab) has been approved in the
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
